[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100564048":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":34,"responsibleParty":61,"collaborators":65,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":19,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":19,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":37,"whyStopped":19,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Early transjugular intrahepatic portosystemic shunt (TIPS)","EXPERIMENTAL","TIPS was performed within 72 hours after the endoscopic hemostasis.",[13],"Procedure: Early TIPS",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"PROCEDURE","Early TIPS",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Feng Duan, MD","Chinese PLA General Hospital","STUDY_DIRECTOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":19,"email":30},"Qunfang Zhou, MD","CONTACT","86 19868000115","zhouqun988509@163.com",{"name":22,"role":28,"phone":32,"phoneExt":19,"email":33},"86 13910984586","duanfeng@vip.sina.com",[35,54],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Chinese PLA General hospital","RECRUITING","Beijing","Beijing Municipality","100853","China","CN",{"type":44,"coordinates":45},"Point",[46,47],116.39723,39.9075,{"lat":47,"lon":46},[50,52],{"name":27,"role":28,"phone":51,"phoneExt":19,"email":30},"8619868000115",{"name":22,"role":28,"phone":53,"phoneExt":19,"email":33},"8613910984586",{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":55,"geoPoint":57,"contacts":58},{"type":44,"coordinates":56},[46,47],{"lat":47,"lon":46},[59,60],{"name":27,"role":28,"phone":29,"phoneExt":19,"email":30},{"name":22,"role":28,"phone":32,"phoneExt":19,"email":33},{"type":62,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"PRINCIPAL_INVESTIGATOR","Zhou Qunfang","Clinical Professor",[66],{"name":23,"class":6},"100564048","early-transjugular-intrahepatic-portosystemic-shunt-for-advanced-hepatocellular-carcinoma-100564048",false,"NCT06624098","Early Transjugular Intrahepatic Portosystemic Shunt for Advanced Hepatocellular Carcinoma","Early Transjugular Intrahepatic Portosystemic Shunt for Advanced Hepatocellular Carcinoma With Main Trunk Portal Vein Tumor Thrombus Induced Gastrointestinal Bleeding: a Multicenter Phase II Study","Inclusion Criteria:\n\n1. diagnosis of primary HCC, confirmed histologically or clinically according to the criteria of the American Association for the Study of Liver Diseases;\n2. presence of PVTT with III-IV grade by Cheng's criteria;\n3. having PVTT induced portal hypertension;\n4. TIPS was performed within 72 hours after the endoscopic hemostasis;\n5. metastases with limited five sites and no more two organs involved;\n6. number of Intrahepatic tumors were no more than five;\n7. receipt of Lenvatinib and PD-1 inhibitor as the first-line systemic therapy;\n8. classified as Child-Pugh class A or B and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 2;\n9. no history of other malignancies;\n10. agreed to participated in this clinical trial;\n11. Hemameba ≥3.0 x109\u002FL, neutrophil ≥1.5x109\u002FL, hemoglobin≥10.0 g\u002FL, platelet≥100x 109\u002FL, ALT; AST; bilirubin ≤1.5-fold normal, GFR≥60ml\u002Fmin.\n\nExclusion Criteria:\n\n1. recurrent HCC;\n2. PVTT at I-II grade by Cheng's criteria;\n3. age \\\u003C 18 years or \\> 75 years;\n4. advanced HCC with more than five metastases;\n5. Number of Intrahepatic tumors were more than five;\n6. no response to Lenvatinib;\n7. life expectancy less than 3 months.","ALL","18 Years","75 Years",{"count":78,"type":79},22,"ESTIMATED","INTERVENTIONAL",[82],"NA","Hepatocellular carcinoma (HCC) with main trunk portal vein tumor thrombus (PVTT) has poor prognosis. The main lethiferous factor is the upper gastrointestinal hemorrhage by PVTT-related portal hypertension. Studies have proven that early transjugular intrahepatic portosystemic shunt (TIPS) with 72 hours after acute variceal bleeding is effective.",[85,86],"Advanced Hepatocellular Carcinoma","Variceal Bleeding",[88,89,90,91],"Advanced hepatocellular carcinoma","Variceal bleeding","Therapeutic endoscopy","Transjugular intrahepatic portosystemic shunt","2024-10-01",{"date":94,"type":95},"2024-10-02","ACTUAL",{"date":92,"type":95},{"date":98,"type":79},"2026-06-30",{"name":5,"class":6},2]